CDH5

(redirected from CD144)

CDH5

A gene on chromosome 16q22.1 that encodes a calcium-dependent cell–cell adhesion glycoprotein (cadherin), which is involved in regulating cell–cell adhesions, mobility and proliferation of epithelial cells. CDH5 is thought to play a key role in endothelial cell biology by controlling cohesion and organisation of intercellular junctions.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Qin, "Elevated circulating VE-cadherin + CD144 + endothelial microparticles in ischemic cerebrovascular disease," Thrombosis Research, vol.
MSCs do not express CD31, CD144, and CD309 (endothelial cell markers) or CD14, CD34, CD45, CD117, and CD133 (hematopoietic cell markers) [61, 79].
Endothelial EVs (CD144, Annexin [V.sup.+ve]) increase production of superoxide anion and hydrogen peroxide in cultured endothelial cells through NADPH oxidase and mitochondria [38, 39], although others suggest that xanthine oxidase may contribute in endothelial (CD144-PE) [40], lymphocytic (CD4, CD3+, CD8, CD11a, Fas, and FasL) [41], and monocyte-derived EVs [42].
EMVs' surface contains many antigen epitopes; CD144 is one of the most commonly used antibodies for identification of EMVs [27].
After four hours of low-tide MV, plasma EMP levels were significantly increased in both the C57BL/6 and TLR4KO mice (P < 0.01 for CD144, P < 0.01 for CD62E, P < 0.01 for CD31, P < 0.05 for CD51, and P < 0.05 for CD54).
Then, the cells were incubated with FITC-conjugated anti-CD44 and CD144, phycoerythrin-conjugated anti-CD34 and CD106, and PerCP-conjugated anti-CD105 antibodies (all from Abcam, Cambridge, UK) for 30 min.
After blocking with 5% bovine serum albumin, cells were incubated overnight at 4[degrees]C with specific primary antibody, which was one of CD31 (PECAM-1), CD54 (ICAM-1), CD106 (VCAM-1) and CD144 (VE-cadherin).
In characterising ADSCs, they phenotypically identify as mesenchymal stem cells by expressing well documented cluster of differentiation (CD) markers, including CD13, CD29, CD31, CD34, CD44, CD63, CD73, CD90, and CD144 [45-49].
For analysis of endothelial progenitor cells (EPCs), fresh whole blood EDTA-anticoagulated samples (100 [micro]L) were incubated for 30 minutes at room temperature with the following monoclonal antibodies: 20 [micro]L of FITC anti-human CD34, 5 [micro]L of PE anti-human CD144 (VE-cadherin), or 5 [micro]L of PE antihuman CD309 (VEGFR-2) (BD PharMingen, Erembodegen, Belgium).
We incubated 10 [micro]L EMP suspension with 10 [micro]L antihuman/rat E-selectin, CD144, CD31, and CD42 or isotype control.
Tumor cells stain for the usual vascular and endothelial markers including CD31, CD34, CD144 (VE-cadherin), and at least focally for factor VIII-related antigen.
Cells were positive for endothelial marker CD31 (96.17% [+ or -] 1.03%), CD144 (VE-Cadherin, 96.77% [+ or -] 0.37%), and KDR (VEGFR2, 60.67% [+ or -] 14.03%) and were negative for the hematopoietic-related antigen CD45 (1.57% [+ or -] 0.40%) and monocyte differentiation antigen CD14 (1.23% [+ or -] 0.26%).